11,307 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in Biohaven Ltd. (NYSE:BHVN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,307 shares of the company’s stock, valued at approximately $565,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BHVN. nVerses Capital LLC acquired a new stake in Biohaven during the 3rd quarter worth approximately $50,000. Redwood Wealth Management Group LLC acquired a new position in shares of Biohaven during the second quarter valued at $61,000. Values First Advisors Inc. bought a new position in Biohaven in the 3rd quarter worth about $78,000. US Bancorp DE increased its position in Biohaven by 57.1% in the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after acquiring an additional 790 shares during the period. Finally, KBC Group NV lifted its holdings in Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after purchasing an additional 443 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Buying and Selling at Biohaven

In other news, Director Gregory Bailey bought 5,000 shares of the business’s stock in a transaction on Tuesday, September 24th. The stock was purchased at an average price of $44.19 per share, with a total value of $220,950.00. Following the transaction, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The trade was a 0.31 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John W. Childs purchased 21,052 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the transaction, the director now owns 21,052 shares of the company’s stock, valued at $999,970. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BHVN. Royal Bank of Canada lowered their price target on Biohaven from $66.00 to $58.00 and set an “outperform” rating on the stock in a research report on Monday, November 25th. Leerink Partners upped their price target on Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Sanford C. Bernstein boosted their price objective on shares of Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a research report on Tuesday, September 24th. William Blair upgraded shares of Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Finally, HC Wainwright reissued a “buy” rating and set a $59.00 target price on shares of Biohaven in a research note on Tuesday, November 26th. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $62.75.

Biohaven Price Performance

Biohaven stock opened at $46.01 on Monday. Biohaven Ltd. has a one year low of $26.80 and a one year high of $62.21. The company’s fifty day moving average price is $49.77 and its two-hundred day moving average price is $41.40. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of -4.92 and a beta of 1.31.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, sell-side analysts anticipate that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.